Here’s a good example of the advantage of being early in biotech.
Before Moderna went public in 2018, it had no products on the market.
It was a microcap focused on the once-obscure niche of messenger RNA products…
And its share price stayed well below $30 for its first year of trading.
But once news leaked that its COVID vaccine would win FDA approval in Dec. 2020…
The stock went on a tear from $29 in March 2020 to $451 in September 2021.
Of course, the rally was driven by worldwide COVID-19 vaccination.
And since the world has moved on, it’s understandable the stock now sits at $118.
STILL, the one thing you’ll notice is the clear advantage of being early.
If you bought at $50, you didn’t profit as much as the guy who bought at $29.
The trick is knowing the best time to get in and out for maximum returns and… A proven way to get your timing right is to follow the paper trail of insiders.
See how we do it in this episode of Insiders Exposed.
Original Post Can be Found Here